v3.26.1
Related Party Transactions - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 19, 2024
Aug. 31, 2024
Sep. 30, 2025
Nov. 30, 2023
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Nov. 28, 2023
Related Party Transaction [Line Items]                      
Revenue [1]         $ 22,357,000 $ 17,203,000 $ 37,829,000 $ 37,808,000      
Proceeds from sale of stock             $ 25,503,000 17,782,000      
Minimum | Tempus                      
Related Party Transaction [Line Items]                      
Percentage of common stock owned         10.00%   10.00%        
Tempus Agreement                      
Related Party Transaction [Line Items]                      
Market development fees received     $ 6,000,000                
Tempus Agreement | Tempus                      
Related Party Transaction [Line Items]                      
Market development fees       $ 6,000              
Revenue         $ 100,000 100,000 $ 300,000 500,000      
Receivable         100,000   $ 100,000   $ 400,000    
Tempus Agreement | Maximum                      
Related Party Transaction [Line Items]                      
Percentage of its gross revenues attributable to such license             20.00%        
Tempus Agreement | Minimum                      
Related Party Transaction [Line Items]                      
Percentage of its gross revenues attributable to such license             10.00%        
Tempus Agreement | First Warrant | Tempus                      
Related Party Transaction [Line Items]                      
Warrant issued to purchase stock                     9,218,800
Warrant exercise price per share                     $ 2
Investment Agreement | Tempus                      
Related Party Transaction [Line Items]                      
Number of shares issued   3,500,000                  
Share price   $ 5.07                  
Investment Agreement with Merck | Merck Sharp & Dohme LLC                      
Related Party Transaction [Line Items]                      
Number of shares issued 14,044,943                    
Share price $ 3.56                    
Proceeds from sale of stock $ 50,000,000                    
Agreement reserve 10,000,000                    
Stock issuance cost $ 300,000                    
Invoice amount         $ 8,300,000 $ 1,900,000 $ 11,200,000 $ 2,400,000      
Receivable                 $ 2,000,000 $ 7,400,000  
[1] Includes related party revenue of $8.4 million and $1.9 million for the three months ended June 30, 2026 and 2025, respectively, and $11.5 million and $2.4 million for the six months ended June 30, 2026 and 2025, respectively.